Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30322743 | 0.83 | CACNA1G (0.41) | DAGLASLC6A2SLC6A4SLC6A3CACNA1G | |
| SCHEMBL1706339 | 0.78 | DAGLA (0.43) | DAGLASLC6A2SLC6A4SLC6A3CACNA1G | |
| SCHEMBL18685939 | 0.78 | DAGLA (0.43) | DAGLASLC6A2SLC6A4SLC6A3CACNA1G | |
| SCHEMBL16011533 | 0.78 | DAGLA (0.43) | DAGLASLC6A2SLC6A4SLC6A3CACNA1G | |
| SCHEMBL19590777 | 0.77 | DAGLA (0.45) | DAGLASLC6A2SLC6A4SLC6A3CACNA1G | |
| SCHEMBL2116168 | 0.76 | DAGLA (0.43) | DAGLASLC6A2SLC6A4SLC6A3CACNA1G | |
| SCHEMBL16130104 | 0.76 | DAGLA (0.43) | DAGLASLC6A2SLC6A4SLC6A3CACNA1G | |
| SCHEMBL19595758 | 0.75 | DAGLA (0.41) | DAGLASLC6A2SLC6A4SLC6A3CACNA1G | |
| SCHEMBL2554277 | 0.75 | HTT (0.49) | NPSR1 | |
| SCHEMBL1974766 | 0.74 | DAGLA (0.42) | DAGLASLC6A2SLC6A4SLC6A3CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648724-B1 | HYDROXYLATED AMINOTRIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-9346793-B2 | Hydroxylated aminotriazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2013-10-10 | — | — | US | disclosed |
| WO-2012077051-A1 | HYDROXYLATED AMINOTRIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | ADORA1, ADORA3, HCAR3 | DAGLA 4565/4885SLC6A2 1047/4885SLC6A4 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.